Outrage of the Month: Lifesaving Insulin Remains Unaffordable for Too Many U.S. Patients January 1, 2023
Letters, Testimony & Filings Letter to the FDA Opposing Approval of Daprodustat and Other Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors December 14, 2022
Letters, Testimony & Filings Testimony Before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding Omecamtiv Mecarbil For the Treatment of Heart Failure December 13, 2022
Letters, Testimony & Filings Letter to the FDA Opposing Marketing Authorization of AvertD for Identifying Patients at Increased Genetic Risk of Opioid Use Disorder December 7, 2022
Press Releases Biden Administration Should Not Delay Support for Waiver of WTO Rules That Limit Access to COVID Tests, Treatments December 6, 2022
Outrage of the Month: Congress Reauthorizes FDA-Corrupting User Fees for Five More Years December 1, 2022
Letters, Testimony & Filings Letter Urging Pfizer to Not Push IP Legal Fees Onto Developing Countries November 29, 2022
Comments on the FDA’s Proposed Rule Regarding Nonprescription Drug Products With an Additional Condition for Nonprescription Use November 25, 2022